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34 percutaneous implantable valves; one patient underwent the implantation of both, a
mitral and an aortic valve device during the same pracedure. Both, the Edwards-Sa-
pien and the CoreValve devices were used. Outcomes were evaluated using the VARC
2 criteria.
Results: Valve-in-Valve in the aortic position (N¼23): mean age of patients was 81.4
 5.9 years. The CoreValve and the Edwards-Sapien valve devices were used in
91.3% and 8.7% of patients, respectively. The CoreValve device was implanted via
the trans-axillar route in 3 cases and via trans-femoral route in 18 cases. The trans-
apical route was used in both Edwards-Sapien implantations. Procedural success was
achieved in 100% of cases. One month and one year survival rates were 100% and
90%; respectively. At one month follow up, 95.7% of patients were in NYHA I/II.
Valve-in-Valve in the mitral position (N¼10): mean age of patients was 73.6  15
years. All the procedures were performed with the Edwards-Sapien device via the
trans-apical route. Procedural success was achieved in 100% of cases. One month and
one year survival rates were 90% and 80%; respectively. At one month follow up,
100% of patients were in NYHA I/II. Valve-in-Valve in the tricuspid position (N¼1):
A 78 year-old patient NYHA IV, was treated with the successful trans-femoral vein
implantation of an Edwards-Sapien 29mm valve within a severely stenotic bio-
prosthetic Handcock 31mm valve. The procedure went uneventful. At one month
follow up the patient was in NYHA II. Pre- and post- peak and mean trans-valvular
gradients were 26/16 and 6/3 mmHg, respectively.
Conclusions: In our experience, the Valve-in-Valve procedure for the treatment of
failed bio-prosthetic valves, using multiple access techniques and available devices,
led to signiﬁcant symptomatic improvement, low peri-procedural morbidity and low
mortality rates.
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Background: Elevated levels of natriuretic peptides are associated with adverse
outcome across a wide spectrum of cardiovascular diseases. However, cut-off values
differ according to age, gender, and body weight. We studied the prognostic value of
plasma N-terminal pro-brain natriuretic peptide (NT-proBNP)-ratio, which is inde-
pendent of individual cut-off levels, in predicting mortality in patients undergoing
transcatheter aortic valve replacement (TAVR).
Methods: Out of 350 consecutive TAVR patients, 244 patients with pre-procedural
NT-proBNP levels were included in the analysis, and the predictive value of NT-
proBNP-ratio (measured NT-proBNP/maximal normal NT-proBNP values speciﬁc for
age and gender) on all-cause-mortality was assessed in a multivariate model.
Results: Median BNP-ratio was 4.2 [interquartile range 1.8-9.7). All-cause mortality
was 7.8% at 30 days, and 16.9% at 1 year, respectively. All-cause mortality at 30 days
was 3.4% in patients with less than median NT-proBNP-ratio, and 14.0% in patients
with more than median NT-proBNP-ratio (p¼0.02). All-cause mortality at 1 year was
7.0% in patients with less than median NT-proBNP-ratio, and 26.8% in those with
more than median NT-proBNP-ratio (p¼0.003). Cumulative survival declined with
increasing quartiles of BNP-ratio (log rank p¼0.001). All patients with a NT-proBNP-
ratio below 1.79 (62/62; 100%) survived at 1 year follow-up. In ROC analysis, NT-
proBNP-ratio signiﬁcantly predicted 30-day (AUC¼0.72; CI¼0.61, 0.83; p¼0.002)
and 1-year all-cause mortality (AUC¼0.71; CI¼0.61, 0.81; p¼0.001). By multivariate
Cox regression analysis including baseline characteristics and NT-proBNP-ratio, both
chronic obstructive pulmonary disease and NT-proBNP-ratio were the only inde-
pendent predictors of all-cause mortality.
Conclusions: NT-proBNP-clinical-activation is associated with increased short- and
long-term mortality after TAVR, and independently predicts all-cause mortality.
Hence, NT-proBNP-clinical-activation should be considered in risk stratiﬁcation for
patients undergoing TAVR.
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Vancouver, British Columbia, 9University of British Columbia, Vancouver, CanadaB224 JACC Vol 64/11/Suppl B j SepBackground: Transcatheter aortic valve replacement (TAVR) requires optimal sizing
of the transcatheter heart valve (THV). Undersizing may result in paravalvular
regurgitation (PVR), while excessive oversizing may result in annular injury. Some
patients have a borderline annular size that ﬁts between two available THV sizes. One
strategy is intentional underexpansion of an oversized THV.
Methods: Thirty one patients underwent TAVR with an intentionally underexpanded
Sapien XT or Sapien 3 THV (Edwards Lifesciences Inc., CA, USA). THVs were
intentionally underexpanded when there was >20% computed tomography (CT)
annular area oversizing or >10% area oversizing with adverse root features. The
deployment balloon was ﬁlled with 5-10% less volume than the manufacturer’s rec-
ommended volume. Transthoracic echocardiography (TTE) and cardiac CT were
performed in all patients immediately post-implant. At 1 year, 31/31 patients (100%)
underwent repeat TTE and 22/31 (71%) underwent repeat CT.
Results: There was no signiﬁcant change in THV hemodynamics or stent size at 1
year. Mean trans-aortic gradient was 124 mmHg immediately post-implant and
126 mmHg at 1 year (p¼0.3). Mean aortic valve area was 1.70.3 cm2 imme-
diately post-implant and 1.60.5 cm2 at 1 year (p¼0.4). PVR was mild or less in
31/31 patients (100%) immediately post-implant and in 30/31 patients (97%) at 1
year. One patient had moderate PVR at 1 year. CT derived stent frame area
immediately post-implant and at 1 year was 4.90.9 cm2 and 5.10.9 cm2
respectively at stent inﬂow (p¼0.05), 5.11.0 cm2 and 5.21.0 cm2 respectively at
mid stent (p¼0.5), 5.30.9 cm2 and 5.20.9 respectively at stent outﬂow (p¼0.5).
There was no signiﬁcant difference in stent frame short and long axis immediately
post-implant versus 1 year, either at the stent inﬂow, mid stent or stent outﬂow (all
p-values >0.05).
Conclusions: There was no signiﬁcant change in THV hemodynamic function and
stent frame expansion 1 year following TAVR with an intentionally underexpanded
balloon-expandable THV. In selected patients in whom excessive oversizing is a
concern, a strategy of intentional underexpansion may reduce the risk of annular
injury without compromising valve performance.
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Background: Transcatheter aortic valve implantation (TAVI) is a minimally invasive
alternative to surgical aortic valve replacement (SAVR) in high risk surgical patients.
Pooled meta-analysis was attempted to analyze the risk of developing permanent heart
block following TAVI.
Methods: All electronic databases were queried for published studies on TAVI and
SAVR. Studies reporting the outcomes of TAVI procedure were included. Exclusion
criteria applied was: studies lacking SAVR as controls, studies comparing trans-apical
versus trans-femoral TAVI procedures and studies not reporting on the outcome of
heart block or pacemaker implantation.
Results: A total of 21 studies with a total of 5061 patients were included in the
study and 2692 of these had TAVI. The risk of permanent heart block necessitating
pacemaker implantation was very high in the patients undergoing TAVI comparedtember 13–17, 2014 j TCT Abstracts/Valvular disease - Aortic: TAVR
